Bausch Health Companies Inc. (BHC) Stock

About Bausch Health Companies Inc.

Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.

Bausch Health Companies Inc. (BHC) stock trades at $4.58 with a market capitalization of $1.71B. The stock is valued at a price-to-earnings (P/E) ratio of -1.38, price-to-book of -0.80, price-to-sales of 0.16. Over the past 52 weeks the stock has ranged between $4.33 and $8.69, and currently trades 47.3% below its 52-week high.

On profitability, Bausch Health Companies Inc. generates a return on equity (ROE) of 120.75% — well above the market average, a sign of a high-quality business, return on capital employed of 12.11%, an operating margin of 21.28%, a net profit margin of -11.27%.

Official website: www.bauschhealth.com